Bayer gets court approval for $7.25 bln Roundup settlement as EPA eyes new science
A Missouri judge has approved a landmark $7.25 billion settlement in nationwide litigation over allegations that exposure to Roundup herbicide can cause cancer, capping more than a decade of litigation that has seen hefty jury awards in favor of cancer victims.
In the Nov. 20 decision, Missouri Circuit Court Judge Timothy Boyer said “this is a substantial and reasonable settlement considering the risks of litigating these cases.”
Bayer, the German conglomerate that bought Monsanto in 2018 and inherited the litigation, celebrated the news. Bayer CEO Bill Anderson said in a statement that approval was a “decisive milestone in the company’s strategy to mitigate the risks of both pending and future Roundup litigation.”
A timely exit
The approval of the settlement provides a timely exit from the costly litigation for Bayer, and comes amid heightened scrutiny of glyphosate, the active chemical ingredient in Roundup and other herbicide brands. Monsanto brought the chemical to the market in the 1970s and drove it to become the world’s most widely used weed killer.
The US Environmental Protection Agency (EPA) is conducting a new review of glyphosate safety, and recently published scientific studies have underscored evidence associating glyphosate and products such as Roundup with cancer.
Over 100 class members filed objections to the settlement agreement represented by some of the lawyers who initiated the Roundup litigation a decade ago. Those lawyers and their clients argued that the settlement is a “sweetheart deal” that violates the US Constitution and involved collusion between Bayer and the group of plaintiffs’ lawyers who drew up the deal. The objectors said the deal enriches the lawyers and benefits Bayer without providing much benefit to the plaintiffs.
Among the complaints they had with the deal is the fact that Bayer can continue to sell the products without cancer warnings but will be largely shielded from hefty future punitive damages as have been awarded in some jury trials.
Bayer and the lawyers who helped structure the deal said the deal was fair and was the best way to ensure that Bayer did not have to put its herbicide business into bankruptcy. They also said that the deal benefits plaintiffs who may never get a trial due to the lengthy backlog of cases.
In his ruling, Judge Boyer sided with Bayer and the supporting plaintiffs’ lawyers, saying the objections were not persuasive. He found that the settlement agreement was negotiated between Bayer and the lawyer group in “hard fought arm’s-length, non-collusive negotiations. He noted that the settlement received support from law firms handling a substantial share of the still-outstanding lawsuits.
Judge Boyer did lower the amount of attorneys fees to be paid to the law firms who negotiated the deal with Bayer from the requested amount of $675 million to $600 million. The lawyers are to receive their payments over seven years, while payments to plaintiffs will take place over up to 21 years, the judge noted.
Subject to appeal
The settlement includes plaintiffs who allege exposure to Roundup prior to February 17, 2026, and have a medical diagnosis of NHL now or receive a medical diagnosis of NHL before the end of a 16-year period following the effective date of the agreement. To fund the class settlement, Bayer said it will make declining capped annual payments over the term of up to 21 years.
Bayer noted the agreement is subject to appeal, which would delay payments to plaintiffs.
Approval of the settlement comes only a few months after Bayer won a US Supreme Court ruling that eliminated a key claim brought by plaintiffs in the Roundup litigation – that the company failed to warn of a risk of cancer.
The Supreme Court ruled 7-2 that federal law preempts state-based claims that a company failed to warn of a pesticide risk if the EPA did not require such a warning.
More than 100,000 people around the US sued Monsanto after the International Agency for Research on Cancer (IARC) in 2015 classified glyphosate as probably carcinogenic to humans, based on a review of a wide body of published studies. IARC noted a particular association to non-Hodgkin lymphoma (NHL).
The EPA has steadfastly rejected that classification, and the Trump administration actively backed Bayer in its Supreme Court case. President Donald Trump also earlier this year issued an executive order protecting and promoting glyphosate as a critical tool for food production.
New science
Monsanto, and subsequently Bayer, has defended glyphosate safety and said there is no valid evidence it causes cancer.
But many independent scientists dispute that and point to a range of studies linking cancer and other harmful health effects with exposure to glyphosate products.
In one of the most recent research findings, scientists from the US National Institute of Environmental Health Sciences (NIEHS) conducted a review of epidemiology studies and found that “the current body of epidemiology studies found a positive association between [glyphosate based herbicide] exposure and [lymphohematopoietic cancers],” including NHL.
The review is a pre-print, meaning it has not yet been peer-reviewed and finalized.
Multiple studies have found a range of harmful effects from glyphosate exposure. A 2022 study, for example, found that glyphosate can have neurotoxic effects at doses lower than levels considered safe by regulatory agencies. And a 2023 study linked childhood exposure to glyphosate to liver inflammation and metabolic disorders.
Last year, a review of 15 years of published studies confirmed that human exposures to glyphosate herbicides have been associated with numerous adverse health outcomes that not only include cancers, liver and metabolic problems, but also reproductive and endocrine-system effects, and disruption of the microbiome, among others.
Also last year, a two-year animal study determined that glyphosate was capable of causing a number of benign and malignant tumors, and that glyphosate products that include other chemicals may enhance the carcinogenicity of glyphosate.
An animal study, published in July of this year also showed harmful effects of glyphosate exposure.
EPA evaluation
The EPA, which has been under pressure from public health advocates to restrict glyphosate use, announced in September that it was joining with the Department of Health and Human Services (HHS) to “strengthen scientific coordination” and “expand the evidence” for the EPA’s ongoing registration review of glyphosate.
The agency is conducting an “open literature search” to inform its updated glyphosate human health risk assessment, which it said would be completed by the end of this year. The comment period ends Nov. 23.